Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive Not Recruiting
NCT04257578Phase 1, Phase 2Updated Jun 25, 2026
Sponsor: University of Washington
B-Cell Non-Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · High Grade B-Cell Lymphoma · Primary Mediastinal (Thymic) Large B-Cell Lymphoma
United States
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)Active Not Recruiting
NCT04529772Phase 3Updated Jun 25, 2026
Sponsor: Acerta Pharma BV
Diffuse Large B-Cell Lymphoma
United States, Australia, Austria, Belgium, Brazil +18 more
Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney DiseaseRecruiting
NCT06824987Phase 2Updated Jun 25, 2026
Sponsor: AstraZeneca
APOL1-Mediated Kidney Disease
United States, United Kingdom
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.Recruiting
NCT07652658Phase 2Updated Jun 25, 2026
Sponsor: AstraZeneca
Idiopathic Pulmonary Fibrosis (IPF)
United States, Argentina, Australia, Bulgaria, Canada +17 more
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive PatientsActive Not Recruiting
NCT06121401Phase 4Updated Jun 25, 2026
Sponsor: Mario Negri Institute for Pharmacological Research
Carcinoma, Ovarian Epithelial
Italy
Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabRecruiting
NCT07363642Phase 3Updated Jun 25, 2026
Sponsor: AstraZeneca
Severe Asthma
China
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).Completed
NCT05742802Phase 3Updated Jun 25, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Australia, Belgium, Brazil +32 more
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersRecruiting
NCT06659029N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Systemic Lupus Erythematosus
United States
AZD5305 hADME in Patients With Advanced Solid MalignanciesRecruiting
NCT06713369Phase 1Updated Jun 24, 2026
Sponsor: AstraZeneca
Locally Advanced or Metastatic Solid Tumor
United Kingdom
A Non-interventional, Prospective Study With BenralizumabRecruiting
NCT06422078N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Asthma, Bronchial
Germany
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)Recruiting
NCT06883305Phase 3Updated Jun 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Brazil, Canada, Chile, China +13 more
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Recruiting
NCT06878261Phase 3Updated Jun 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
United States, Argentina, Australia, Belgium, Bulgaria +17 more
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseRecruiting
NCT06283966Phase 3Updated Jun 24, 2026
Sponsor: AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease)
United States, Argentina, Australia, Austria, Brazil +32 more
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine CareRecruiting
NCT07424261N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Lupus Erythematosus, Systemic
Germany
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.Recruiting
NCT06137144Phase 1, Phase 2Updated Jun 24, 2026
Sponsor: AstraZeneca
Lymphoma · Non-Hodgkin Lymphoma · Hodgkin Lymphoma · Peripheral T-cell Lymphoma (PTCL)
United States, Australia, China, France, Germany +5 more
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)Recruiting
NCT06890273N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Endometrial Cancer
Germany
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy ParticipantsActive Not Recruiting
NCT07534592Phase 1Updated Jun 24, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]Completed
NCT06511193N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Canada
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisRecruiting
NCT07276581Phase 2Updated Jun 24, 2026
Sponsor: AstraZeneca
Rheumatoid Arthritis
United States, Argentina, Brazil, Bulgaria, Canada +12 more
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)Recruiting
NCT06472310N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Severe Asthma
Russia
Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruiting
NCT06995833N/AUpdated Jun 24, 2026
Sponsor: AstraZeneca
Endometrial Cancer
South Korea
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's DiseaseTerminated
NCT03759288Phase 2, Phase 3Updated Jun 23, 2026
Sponsor: AstraZeneca
Crohn's Disease · IBD
United States, Canada, Czechia, Germany, Hungary +12 more
Open-label Extension Study of Brazikumab in Ulcerative ColitisTerminated
NCT04277546Phase 2Updated Jun 23, 2026
Sponsor: AstraZeneca
Ulcerative Colitis
United States, Czechia, Germany, Israel, Italy +6 more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)Active Not Recruiting
NCT05555732Phase 3Updated Jun 23, 2026
Sponsor: Daiichi Sankyo
Metastatic Non Small Cell Lung Cancer
United States, Argentina, Australia, Austria, Belgium +24 more
Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative ColitisTerminated
NCT03616821Phase 2Updated Jun 23, 2026
Sponsor: AstraZeneca
Ulcerative Colitis · IBD
United States, Canada, Czechia, Germany, Hungary +14 more

Previous page Next page